The road not taken

A company does something sleazy, and pays $465 million in settlement.  But the company’s senior executives don’t get a salary hit.

“EpiPen Pact Unlikely to Affect Pay,” The Wall Street Journal, October 28, 2016 B2.  Mylan execs won’t suffer because their compensation is determined based on adjusted earnings that exclude the cost of settlements, such as the one the company is paying to the US Gov following allegations of Medicaid overcharges for the EpiPen.

Too bad the returns to the shareholders can’t be computed the same way.  What about the Board that agreed to this formula?  Didn’t directors use to have a fiduciary duty?


Leave a comment

Filed under Board, Controls, Directors, Duty, Duty of Care, Governance, Internal controls, Investor relations, Oversight, Oversight, Policy, Protect assets

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s